kamel Mamchaoui

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2549608/publications.pdf

Version: 2024-02-01

57 papers	2,735 citations	159358 30 h-index	189595 50 g-index
59 all docs	59 docs citations	59 times ranked	4345 citing authors

#	Article	IF	Citations
1	Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell, 2007, 6, 515-523.	3.0	239
2	Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skeletal Muscle, 2011, 1, 34.	1.9	228
3	Rescue of nonsense mutations by amlexanox in human cells. Orphanet Journal of Rare Diseases, 2012, 7, 58.	1.2	131
4	Nesprin-1Î±-Dependent Microtubule Nucleation from the Nuclear Envelope via Akap450 Is Necessary for Nuclear Positioning in Muscle Cells. Current Biology, 2017, 27, 2999-3009.e9.	1.8	125
5	Autologous Myoblast Transplantation for Oculopharyngeal Muscular Dystrophy: a Phase I/Iia Clinical Study. Molecular Therapy, 2014, 22, 219-225.	3.7	116
6	Inhibition of Chikungunya Virus Infection in Cultured Human Muscle Cells by Furin Inhibitors. Journal of Biological Chemistry, 2008, 283, 21899-21908.	1.6	114
7	Cellular micro-environments reveal defective mechanosensing responses and elevated YAP signaling in LMNA-mutated muscle precursors. Journal of Cell Science, 2014, 127, 2873-84.	1.2	105
8	Laminopathies disrupt epigenomic developmental programs and cell fate. Science Translational Medicine, 2016, 8, 335ra58.	5.8	91
9	Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders. American Journal of Human Genetics, 2016, 98, 90-101.	2.6	86
10	Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation. Neuromuscular Disorders, 2006, 16, 770-781.	0.3	66
11	Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds. DMM Disease Models and Mechanisms, 2017, 10, 487-497.	1.2	65
12	Generation of Isogenic D4Z4 Contracted and Noncontracted Immortal Muscle Cell Clones from a Mosaic Patient. American Journal of Pathology, 2012, 181, 1387-1401.	1.9	63
13	Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Molecular Therapy, 2017, 25, 2561-2572.	3.7	63
14	Telomerase can extend the proliferative capacity of human myoblasts, but does not lead to their immortalization. Molecular Cancer Research, 2003, 1, 643-53.	1.5	62
15	Gene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In. Human Gene Therapy, 2013, 24, 692-701.	1.4	61
16	Immortalized Skin Fibroblasts Expressing Conditional MyoD as a Renewable and Reliable Source of Converted Human Muscle Cells to Assess Therapeutic Strategies for Muscular Dystrophies: Validation of an Exon-Skipping Approach to Restore Dystrophin in Duchenne Muscular Dystrophy Cells. Human Gene Therapy, 2009, 20, 784-790.	1.4	60
17	Skeletal muscle characteristics are preserved in hTERT/cdk4 human myogenic cell lines. Skeletal Muscle, 2016, 6, 43.	1.9	57
18	Membrane repair of human skeletal muscle cells requires Annexin-A5. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2267-2279.	1.9	56

#	ARTICLE	IF	CITATIONS
19	A novel long non-coding RNA Myolinc regulates myogenesis through TDP-43 and Filip1. Journal of Molecular Cell Biology, 2018, 10, 102-117.	1.5	56
20	Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Journal of Clinical Investigation, 2016, 126, 4237-4249.	3.9	46
21	Shift from Extracellular Signal-Regulated Kinase to AKT/cAMP Response Element-Binding Protein Pathway Increases Survival-Motor-Neuron Expression in Spinal-Muscular-Atrophy-Like Mice and Patient Cells. Journal of Neuroscience, 2013, 33, 4280-4294.	1.7	45
22	Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation. European Journal of Human Genetics, 2011, 19, 647-654.	1.4	44
23	Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System. Molecular Therapy - Nucleic Acids, 2017, 7, 11-19.	2.3	44
24	RyR1 Deficiency in Congenital Myopathies Disrupts Excitation-Contraction Coupling. Human Mutation, 2013, 34, 986-996.	1.1	40
25	Alleleâ€specific silencing therapy for Dynamin 2â€related dominant centronuclear myopathy. EMBO Molecular Medicine, 2018, 10, 239-253.	3.3	40
26	Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Research and Therapy, 2013, 15, R131.	1.6	37
27	Unveiling the degradative route of the V247M Î±-sarcoglycan mutant responsible for LGMD-2D. Human Molecular Genetics, 2014, 23, 3746-3758.	1.4	36
28	Lamins and nesprin-1 mediate inside-out mechanical coupling in muscle cell precursors through FHOD1. Scientific Reports, 2017, 7, 1253.	1.6	35
29	Exons 45â€“55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene. Molecular Therapy, 2019, 27, 2005-2017.	3.7	35
30	Dystrophin rescue by trans -splicing: a strategy for DMD genotypes not eligible for exon skipping approaches. Nucleic Acids Research, 2013, 41, 8391-8402.	6.5	34
31	A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies. JCI Insight, 2019, 4, .	2.3	33
32	Alternative splicing of clathrin heavy chain contributes to the switch from coated pits to plaques. Journal of Cell Biology, 2020, 219, .	2.3	31
33	Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target. Redox Biology, 2022, 51, 102251.	3.9	31
34	Synthetically modified mRNA for efficient and fast human iPS cell generation and direct transdifferentiation to myoblasts. Biochemical and Biophysical Research Communications, 2016, 473, 743-751.	1.0	30
35	A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy. Developmental Cell, 2020, 53, 154-168.e6.	3.1	30
36	FUBP1: a new protagonist in splicing regulation of the DMD gene. Nucleic Acids Research, 2015, 43, 2378-2389.	6.5	29

#	ARTICLE	IF	CITATIONS
37	Lamin Mutations Cause Increased YAP Nuclear Entry in Muscle Stem Cells. Cells, 2020, 9, 816.	1.8	28
38	Specific localization of nesprin-1-Î±2, the short isoform of nesprin-1 with a KASH domain, in developing, fetal and regenerating muscle, using a new monoclonal antibody. BMC Cell Biology, 2016, 17, 26.	3.0	26
39	Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy. Scientific Reports, 2020, 10, 1125.	1.6	24
40	Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes. Molecular Therapy - Nucleic Acids, 2019, 16, 246-256.	2.3	22
41	FHL1B Interacts with Lamin A/C andÂEmerin at the Nuclear Lamina andÂisÂMisregulated in Emery-Dreifuss Muscular Dystrophy. Journal of Neuromuscular Diseases, 2016, 3, 497-510.	1.1	17
42	Functional Characterization of a Central Core Disease RyR1 Mutation (p.Y4864H) Associated with Quantitative Defect in RyR1 Protein. Journal of Neuromuscular Diseases, 2015, 2, 421-432.	1.1	16
43	ZNF555 protein binds to transcriptional activator site of 4qA allele andANT1: potential implication in Facioscapulohumeral dystrophy. Nucleic Acids Research, 2015, 43, 8227-8242.	6.5	15
44	Lamin-Related Congenital Muscular Dystrophy Alters Mechanical Signaling and Skeletal Muscle Growth. International Journal of Molecular Sciences, 2021, 22, 306.	1.8	15
45	Regenerative potential of human muscle stem cells in chronic inflammation. Arthritis Research and Therapy, 2011, 13, R207.	1.6	14
46	A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures. PLoS ONE, 2018, 13, e0204485.	1.1	14
47	miR-708-5p and miR-34c-5p are involved in nNOS regulation in dystrophic context. Skeletal Muscle, 2018, 8, 15.	1.9	12
48	Simplified in vitro engineering of neuromuscular junctions between rat embryonic motoneurons and immortalized human skeletal muscle cells . Stem Cells and Cloning: Advances and Applications, 2019, Volume 12, 1-9.	2.3	10
49	Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?. Antioxidants, 2020, 9, 1268.	2.2	10
50	Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides. Nucleic Acid Therapeutics, 2021, 31, 172-181.	2.0	9
51	A functional human motor unit platform engineered from human embryonic stem cells and immortalized skeletal myoblasts. Stem Cells and Cloning: Advances and Applications, 2018, Volume 11, 85-93.	2.3	8
52	Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes. PLoS ONE, 2017, 12, e0181065.	1.1	8
53	Myogenin controls via AKAP6 non-centrosomal microtubule-organizing center formation at the nuclear envelope. ELife, 2021, 10, .	2.8	6
54	Obestatin Increases the Regenerative Capacity of Human Myoblasts Transplanted Intramuscularly in an Immunodeficient Mouse Model. Molecular Therapy, 2017, 25, 2345-2359.	3.7	4

#	ARTICLE	IF	CITATIONS
55	Antisense-Mediated Skipping of Dysferlin Exons in Control and Dysferlinopathy Patient-Derived Cells. Nucleic Acid Therapeutics, 2020, 30, 71-79.	2.0	4
56	A Novel Bioengineered Functional Motor Unit Platform to Study Neuromuscular Interaction. Journal of Clinical Medicine, 2020, 9, 3238.	1.0	4
57	Targeting the Ubiquitin-Proteasome System in Limb-Girdle Muscular Dystrophy With CAPN3 Mutations. Frontiers in Cell and Developmental Biology, 2022, 10, 822563.	1.8	4